Sevelamer Carbonate For Oral Suspension Powder, For Suspension
Product Images NDC 43598-479

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate For Oral Suspension (NDC 43598-479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure2 (Figure 2)

A forest plot chart showing subgroup analyses of mean differences with 95% confidence intervals for Sevelamer Carbonate versus placebo. Subgroups include overall, screening BSA (<1.2, >=1.2), baseline serum phosphorus (<7, >=7 mg/dL), age (<13, >=13 years), and dialysis status (yes, no). The chart compares the mean differences favoring Sevelamer Carbonate or placebo.*

FDA Label Image

Carton1 (Carton1)

Packaging label for Sevelamer Carbonate for Oral Suspension 0.8 g packets, a powder for suspension in citrus flavor. The label indicates it contains 90 packets, is for prescription use only, and lists Dr. Reddys Laboratories Inc. as the distributor, with the product made in India. Directions and inactive ingredients are provided.*

FDA Label Image

Carton2 (Carton2)

Packaging label for Sevelamer Carbonate for Oral Suspension 2.4 g packets, citrus flavor, containing 90 packets. It is a powder for suspension for oral use, labeled Rx only. The label shows directions for use, ingredients, dosage instructions, and storage details. The distributor is Dr. Reddy's Laboratories Inc, made in India.*

FDA Label Image

Figure1 (Figure1)

Chemical structure diagram of the active ingredient Sevelamer Carbonate, showing the molecular formation including ammonium and bicarbonate groups.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the percentage of patients with at least 2-fold reduction from baseline serum phosphorus levels. The x-axis measures reduction in serum phosphorus (mg/dL), ranging from -4 to 8, with indications of worsening or improvement. Two lines represent treatments: Active Control and Sevelamer Hydrochloride, both showing decreasing patient percentages with increased reduction.*

FDA Label Image

Figure4

A line graph depicting the change in phosphorus levels from baseline over a 52-week study period comparing Sevelamer Hydrochloride treatment against an active control. The x-axis represents the study weeks from 0 to 52, and the y-axis shows the phosphorus change values, with Sevelamer Hydrochloride represented by a solid line with square markers and the active control by a dashed line with square markers.*

FDA Label Image

Packet1 (Packet1)

Packaging label for Sevelamer Carbonate for Oral Suspension 0.8 g powder in citrus flavor, distributed by Dr. Reddy's Laboratories Inc. Label includes directions for use, storage instructions, barcode, and NDC 43598-478-01. The label states it is Rx only and shows instructions for opening along a dotted line.*

FDA Label Image

Packet2 (Packet2)

Label for Sevelamer Carbonate for Oral Suspension 2.4 g powder for suspension in citrus flavor. The label indicates it is Rx only and includes the Dr. Reddy's Laboratories Inc logo. Barcode, NDC 43598-479-01, use and storage instructions, and distribution information are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.